Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Filovirus Disease”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)WithdrawnNCT06682234
What this trial is testing

Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus Disease

Who this might be right for
Filovirus DiseasePostexposure Prophylaxis for Filovirus Disease
Gilead Sciences
Testing effectiveness (Phase 2)Study completedNCT02876328
What this trial is testing

Partnership for Research on Ebola VACcinations

Who this might be right for
Ebola Virus Disease
National Institute of Allergy and Infectious Diseases (NIAID) 4,789
Early research (Phase 1)Study completedNCT02240875
What this trial is testing

Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo

Who this might be right for
EbolaEbola Zaire
University of Oxford 91
Not applicableStudy completedNCT02431923
What this trial is testing

Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up

Who this might be right for
Ebola Virus Disease
National Institute of Allergy and Infectious Diseases (NIAID) 4,043
Post-approval studies (Phase 4)Active Not RecruitingNCT05992480
What this trial is testing

REVIVE (Response to the Ebola Virus Vaccine)

Who this might be right for
Ebola Virus Disease
Tulane University 40
Early research (Phase 1)Study completedNCT00605514
What this trial is testing

Ebola and Marburg Virus Vaccines

Who this might be right for
Ebola VaccinesMarburg Virus DiseaseEbola Virus Disease+2 more
National Institute of Allergy and Infectious Diseases (NIAID) 20
Early research (Phase 1)Ended earlyNCT03462004
What this trial is testing

Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein

Who this might be right for
Ebola Virus Disease
National Institute of Allergy and Infectious Diseases (NIAID) 15
Early research (Phase 1)Study completedNCT02564575
What this trial is testing

Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults

Who this might be right for
Hemorrhagic Fever, Ebola
National Institute of Allergy and Infectious Diseases (NIAID) 30
Testing effectiveness (Phase 2)Study completedNCT02289027
What this trial is testing

A Clinical Trial on the Candidate Vaccine cAd3-EBOZ in Healthy Adults in Switzerland

Who this might be right for
Ebola Vaccines
Centre Hospitalier Universitaire Vaudois 120
Testing effectiveness (Phase 2)Study completedNCT05064956
What this trial is testing

Ad26.ZEBOV Booster in HIV+ Adults Previously Vaccinated With Ad26.ZEBOV/MVA-BN-Filo (EBOVAC HIV+ Booster Study)

Who this might be right for
Ebola Virus DiseaseEbolaHiv
London School of Hygiene and Tropical Medicine 26
Not applicableEnded earlyNCT04250168
What this trial is testing

Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response

Who this might be right for
Sepsis BacterialEbola Virus DiseaseBloodstream Infection
Institute of Tropical Medicine, Belgium 43
Early research (Phase 1)Ended earlyNCT02041715
What this trial is testing

Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802

Who this might be right for
Ebola Virus Infection
Arbutus Biopharma Corporation 21
Large-scale testing (Phase 3)Study completedNCT02543268
What this trial is testing

Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

Who this might be right for
Healthy
Crucell Holland BV 329
Not applicableAvailableNCT05067166
What this trial is testing

Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP

Who this might be right for
Ebola Virus Disease
Ridgeback Biotherapeutics, LP
Testing effectiveness (Phase 2)Study completedNCT04186000
What this trial is testing

Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola

Who this might be right for
Ebola Virus Disease
Universiteit Antwerpen 699
Large-scale testing (Phase 3)Study completedNCT02342171
What this trial is testing

Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea

Who this might be right for
Hemorrhagic Fever, Ebola
Institute of Tropical Medicine, Belgium 606
Testing effectiveness (Phase 2)Study completedNCT04711356
What this trial is testing

Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study)

Who this might be right for
Ebola Virus Disease
London School of Hygiene and Tropical Medicine 50
Testing effectiveness (Phase 2)Study completedNCT05817422
What this trial is testing

Monovalent Chimpanzee Adenoviral-Vectored Marburg Virus Vaccine in Healthy Adults

Who this might be right for
Marburg Virus Disease
Albert B. Sabin Vaccine Institute 126
Early research (Phase 1)Study completedNCT02354404
What this trial is testing

Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda

Who this might be right for
Hemorrhagic Fever, Ebola
National Institute of Allergy and Infectious Diseases (NIAID) 90
Not applicableStudy completedNCT02911415
What this trial is testing

Open Study of the Duration of Immunity After Vaccination With GamEvac-Combi

Who this might be right for
Ebola Hemorrhagic Fever
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation 60
Next Page